Normative Values for the German Version of the Montreal Cognitive Assessment (MoCA) (MoCA-Norm)

May 30, 2018 updated by: Andreas Monsch
This observational cohort study in healthy volunteers establishes normative data for the German version of the Montreal Cognitive Assessment (MoCA) and investigates the possible impacts of demographics on the MoCA total score.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The Montreal Cognitive Assessment (MoCA) is a short tool to evaluate a multitude of cognitive domains (visuospatial / executive functioning, object naming, memory, attention, language, abstraction, orientation). The original English MoCA consistently showed very high sensitivity and specificity in distinguishing patients with mild cognitive impairment from healthy controls. Therefore it is an excellent tool for early recognition of cognitive disorders. Based on a Canadian sample, the MoCA proposes a cut-off-value of 26/30 points. However, there is increasing evidence of intercultural differences in terms of the best cut-off-score. In addition the original version only slightly corrects for possible influences of education - an adjustment for age- or gender-related effects is missing. Therefore, the aim of our study was to investigate the possible impacts of demographics on the MoCA total score and to provide normative values for a German-speaking population.

Study Type

Observational

Enrollment (Actual)

334

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

61 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Healthy volunteers

Description

Inclusion Criteria:

  • Age ≥65 years
  • Education ≥7 years
  • Fluency in the German language
  • Written informed consent

Exclusion Criteria:

  • History of cognitive impairment
  • Depression
  • Severe sensory or motor impairment interfering with cognitive testing
  • Serious somatic disease
  • Disease or event affecting the central nervous system
  • Cerebrovascular disease
  • Regular medication with psychoactive drugs except for benzodiazepines
  • Participation in a cognitive study within the last 3 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
MoCA cohort
The German MoCA is administered once to all study participants.
Diagnostic test: MoCA

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Montreal Cognitive Assessment (MoCA) - German version
Time Frame: Baseline
Total score of the MoCA
Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mini-Mental State Examination (MMSE)
Time Frame: Baseline
Total score of the MMSE
Baseline
Geriatric Depression Scale (GDS)
Time Frame: Baseline
Total score of the GDS
Baseline
Consortium to Establish a Registry for Alzheimer's Disease - Neuropsychological Assessment Battery (CERAD-NAB)
Time Frame: Baseline
Total score of the CERAD-NAB
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Andreas Monsch

Investigators

  • Principal Investigator: Alessandra Thomann, MSc, Felix Platter Hospital Basel
  • Principal Investigator: Nicolai Goettel, MD, University Hospital, Basel, Switzerland
  • Principal Investigator: Raphael Monsch, MD, University Hospital, Basel, Switzerland
  • Principal Investigator: Manfred Berres, PhD, University of Applied Sciences Koblenz
  • Study Chair: Andreas Monsch, PhD, Felix Platter Hospital Basel

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2016

Primary Completion (Actual)

April 1, 2017

Study Completion (Actual)

April 1, 2017

Study Registration Dates

First Submitted

August 8, 2017

First Submitted That Met QC Criteria

August 8, 2017

First Posted (Actual)

August 11, 2017

Study Record Updates

Last Update Posted (Actual)

May 31, 2018

Last Update Submitted That Met QC Criteria

May 30, 2018

Last Verified

May 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MoCA-Norm

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cognitive Impairment

Clinical Trials on MoCA

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe